Latest & greatest articles for Hypersensitivity Reaction

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Hypersensitivity Reaction or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Hypersensitivity Reaction and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Hypersensitivity Reaction

1. Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data (Abstract)

Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data To assess the risk of hypersensitivity reactions (HSRs) with allopurinol and febuxostat in a population-based study.We used the 5% Medicare beneficiary sample (≥65 years) from 2006 to 2012 to identify people with a newly filled prescription for allopurinol, febuxostat or colchicine. We used multivariable-adjusted Cox regression analyses to compare the hazard ratio (HR) of incident HSRs

2020 EvidenceUpdates

2. Canadian expert consensus: management of hypersensitivity reactions to intravenous iron in adults Full Text available with Trip Pro

Canadian expert consensus: management of hypersensitivity reactions to intravenous iron in adults Canadian expert consensus: management of hypersensitivity reactions to intravenous iron in adults - Lim - - Vox Sanguinis - Wiley Online Library The full text of this article hosted at iucr.org is unavailable due to technical difficulties.

2019 CPG Infobase

3. Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial. There are currently no approved treatments for peanut allergy.To assess the efficacy and adverse events of epicutaneous immunotherapy with a peanut patch among peanut-allergic children.Phase 3, randomized, double-blind, placebo-controlled trial conducted at 31 sites in 5 countries between January 8, 2016, and August 18, 2017 (...) . Participants included peanut-allergic children (aged 4-11 years [n = 356] without a history of a severe anaphylactic reaction) developing objective symptoms during a double-blind, placebo-controlled food challenge at an eliciting dose of 300 mg or less of peanut protein.Daily treatment with peanut patch containing either 250 μg of peanut protein (n = 238) or placebo (n = 118) for 12 months.The primary outcome was the percentage difference in responders between the peanut patch and placebo patch based

2019 JAMA Controlled trial quality: predicted high

4. True Allergic Reaction to Amide Local Anesthetics Such as Lidocaine Is Confirmed by Immunologic Testing

] AND "hypersensitivity, immediate"[Mesh]) OR "hypersensitivity/immunology"[Mesh] AND "anesthetics, local"[Mesh] Comments on The Evidence Validity: The studies by Fuzier and Sambrook were retrospective in nature and did not include randomization; however, both compiled data from large national databases over extended periods of many years. The follow-up of reported allergic reactions with allergy testing to confirm true allergy also strengthens data reported in the Fuzier study; however, this follow-up (...) a pseudoallergic psychogenic response, and can this be confirmed as an immunologic reaction to the anesthetic agent itself and not to known additives or preservatives? Clinical Bottom Line True allergy to amide local anesthetics such as lidocaine does exist and has been documented as type I and IV hypersensitivity reactions; however, the occurrence of this allergy in the population has been shown to be less than 1%. This should be differentiated from more common psychogenic responses to injection

2016 UTHSCSA Dental School CAT Library

5. Myth or Reality: Are Shellfish Allergies Related to Contrast Reactions?

with the common shellfish allergy had similar reactions after contrast administration, iodine must be the allergen. In fact, many patients, including the one in the anecdote above, use the terminology “iodine allergy” to describe their contrast hypersensitivity. In the survey by Shih-Wen Huang from Asthma and Allergy Proceedings [2], patients were also asked, “Do you think that it is the iodine in the seafood that is responsible for the allergic reaction?” Not surprisingly, 92% of these patients believed (...) . How could she possibly be allergic to something that she had tolerated without problem for 40 years? Moreover, is there any factual basis behind the common recommendation that patients with contrast reactions should avoid shellfish? Conversely, should iodinated contrast agents be avoided in patients with documented seafood allergies? Is there evidence behind this clinical practice, or is it actually just a medical myth? Although it would be virtually impossible to determine when this myth began

2016 Clinical Correlations

6. ASCIA Event record for allergic reactions

of reaction ? Home ? School ? Childcare ? Work ? Dining out ? Other__________________________________________________________________ Activity immediately before reaction: ? Eating ? Gardening ? Exercise ? Other: _________________________________ Other medical conditions ? Asthma ? Other: _______________________________________________________ Previous allergic reactions ? Mild-moderate ? Severe (anaphylaxis) Allergen/s________________________________________________________________ Adrenaline (...) ASCIA Event record for allergic reactions This document should be completed by the patient (to provide to their doctor or nurse practitioner) or completed by the doctor or nurse practitioner. Patient name: _____________________________________________________________ Date and time of reaction: ___________________________________________________ GP: ______________________________Specialist: ______________________________ Suspected trigger/s (if known) ? Food /s

2015 Australasian Society of Clinical Immunology and Allergy

7. Do parents of children with allergic reactions know how to use adrenaline autoinjectors appropriately?

Do parents of children with allergic reactions know how to use adrenaline autoinjectors appropriately? BestBets: Do parents of children with allergic reactions know how to use adrenaline autoinjectors appropriately? Do parents of children with allergic reactions know how to use adrenaline autoinjectors appropriately? Report By: Jennifer Lewis - 4th Year Medical Student Search checked by David Drake - Specialist Trainee in Emergency Medicine Institution: Manchester Royal Infirmary, Manchester (...) were relevant. Relevant Paper(s) Author, date and country Patient group Study type (level of evidence) Outcomes Key results Study Weaknesses Topal et al, 2013, Turkey 64 patients with history of allergic reaction whom had been prescribed an AAI (50 caregivers and 14 children>12 years old) Single centre cross sectional descriptive study Able to perform 6 steps for a successful injection on training device 39.4% of participants were able to complete all 6 steps Author assumes teaching was given

2014 BestBETS

8. Ferumoxytol: risk of serious hypersensitivity reactions?contraindicated if any drug allergy

Ferumoxytol: risk of serious hypersensitivity reactions?contraindicated if any drug allergy Ferumoxytol: risk of serious hypersensitivity reactions—contraindicated if any drug allergy; administer via infusion - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Ferumoxytol: risk of serious hypersensitivity reactions—contraindicated if any drug allergy; administer via infusion New recommendations are being introduced to minimise the risk of serious hypersensitivity reactions (...) article from ). Many of the patients who had a life-threatening or fatal anaphylactic reaction also had a known history of drug allergy to a non-iron product (eg, an antibiotic). New recommendations for ferumoxytol are being introduced as a result of this re-evaluation: Advice for healthcare professionals Prescribing Ferumoxytol is now contraindicated in patients with any known history of drug allergy, including hypersensitivity to other parenteral iron products. As with all IV iron products, the risk

2014 MHRA Drug Safety Update

9. Intravenous iron and serious hypersensitivity reactions

Intravenous iron and serious hypersensitivity reactions Intravenous iron and serious hypersensitivity reactions - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Intravenous iron and serious hypersensitivity reactions Clarification of advice on new recommendations regarding initial test dose. Published 11 December 2014 From: Therapeutic area: , Article date: September 2013 We would like to make you aware that on 9 September 2013, we updated the information in the recent published

2013 MHRA Drug Safety Update

10. Intravenous iron and serious hypersensitivity reactions: strengthened recommendations

Intravenous iron and serious hypersensitivity reactions: strengthened recommendations Intravenous iron and serious hypersensitivity reactions: strengthened recommendations - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Intravenous iron and serious hypersensitivity reactions: strengthened recommendations New strengthened recommendations to manage and minimise risk. Published 11 December 2014 From: Therapeutic area: , Contents Article date: August 2013 Intravenous (IV) iron (...) products are indicated in the treatment of iron deficiency and anaemia when iron supplements cannot be given or have not worked. Hypersensitivity reactions are well known to occur rarely with IV iron products, and may be life-threatening or fatal. Warnings about this risk are given in the product information. European review A European review of IV iron products has taken place after concerns in France about the risk of serious hypersensitivity reactions, especially in pregnant women. The review has

2013 MHRA Drug Safety Update

11. Blue dyes: risk of serious allergic reactions

Blue dyes: risk of serious allergic reactions Blue dyes: risk of serious allergic reactions - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Blue dyes: risk of serious allergic reactions Surgeons reminded to have competent personnel and emergency facilities available for at least 1 hour after administration of the blue dye. Published 11 December 2014 From: Therapeutic area: , Article date: February 2012 Blue dyes such as Patent Blue V imported from the EU are used in lymphatic (...) mapping for sentinel lymph node biopsy (SLNB) in breast surgery. Patent Blue V does not carry a UK marketing authorisation. On the basis of a clinical study (the ALMANAC trial) and follow-up program (the NEW START program) serious allergic reactions were estimated at an incidence rate of 0.1%. Since 1975 a total of 70 case reports of allergic reactions with Patent Blue V were reported to us. 58 of these reports have been received since 2007, 26 of which were serious reactions. With currently

2012 MHRA Drug Safety Update

12. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. Full Text available with Trip Pro

HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. Carbamazepine causes various forms of hypersensitivity reactions, ranging from maculopapular exanthema to severe blistering reactions. The HLA-B*1502 allele has been shown to be strongly correlated with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) in the Han Chinese and other Asian populations but not in European populations.We performed a genomewide association study (...) ), maculopapular exanthema (odds ratio, 8.33; 95% CI, 3.59 to 19.36), and SJS-TEN (odds ratio, 25.93; 95% CI, 4.93 to 116.18).The presence of the HLA-A*3101 allele was associated with carbamazepine-induced hypersensitivity reactions among subjects of Northern European ancestry. The presence of the allele increased the risk from 5.0% to 26.0%, whereas its absence reduced the risk from 5.0% to 3.8%. (Funded by the U.K. Department of Health and others.).

2011 NEJM

13. Prasugrel (Efient?): rare but serious hypersensitivity reactions

reactions including, very rarely, angioedema. As at April 2011, 9 such cases have been reported worldwide in association with use in approximately 727 000 patients. Some cases have occurred in patients with a known history of hypersensitivity to clopidogrel, but others have no history of clopidogrel exposure. At present, the mechanism for these allergic reactions is unclear. The time to onset of symptoms ranged from immediately after treatment to up to 5 to 10 days later. Advice for healthcare (...) should inform their doctor immediately if they experience symptoms suggesting hypersensitivity or allergic reaction (eg, swelling of the face, neck, tongue, lips, or throat; rash; itching; or shortness of breath) Further information See BNF section Article citation: Drug Safety Update May 2011 vol 4 issue 10: A1. Published 11 December 2014 Explore the topic Is this page useful? Thank you for your feedback Help us improve GOV.UK Don’t include personal or financial information like your National

2011 MHRA Drug Safety Update

14. Pharmacological interventions for the prevention of allergic and febrile non-haemolytic transfusion reactions. Full Text available with Trip Pro

Pharmacological interventions for the prevention of allergic and febrile non-haemolytic transfusion reactions. Allergic and febrile non-haemolytic transfusion reactions (NHTRs) are the two most common forms of transfusion reaction. Pretransfusion medication with anti-inflammatory drugs is used in NHTR prevention, however its efficacy and safety remains unclear.To assess the clinical effects and safety of pharmacological interventions for preventing NHTR in patients with and without a history (...) includes three RCTs (two PD and one CD). The PD-RCTs employed disparate units of randomisation (UofR); patient or transfusion, while the CD-RCT applied the patient as the UofR. The PD-RCTs administered leukodepleted blood products. Both PD-RCTs compared acetaminophen plus diphenhydramine (ApD) at different regimens with placebo, while the CD-RCT contrasted hydrocortisone pharmacotherapy with diphenhydramine. Both PD-RCTs found no statistically significant difference in allergic reactions (RR 0.13, 95

2010 Cochrane

15. Panitumumab (Vectibix): serious hypersensitivity reactions

Panitumumab (Vectibix): serious hypersensitivity reactions Panitumumab (Vectibix): serious hypersensitivity reactions - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Panitumumab (Vectibix): serious hypersensitivity reactions New reports of serious hypersensitivity reactions (including anaphylaxis) in patients receiving panitumumab, some of which were fatal. Published 11 December 2014 From: Therapeutic area: Article date: May 2010 Panitumumab (Vectibix) is indicated (...) as monotherapy for the treatment of patients with EGFR (epidermal growth factor receptor)-expressing metastatic colorectal carcinoma with non-mutated (wild type) KRAS after failure of chemotherapy regimens. There have been new reports of serious hypersensitivity reactions (including anaphylaxis) in patients receiving panitumumab, some of which were fatal. A clinical trial report has been received of a fatal case of angioedema occurring 2 days after exposure following a prior episode of angioedema which

2010 MHRA Drug Safety Update

16. Bevacizumab (Avastin): hypersensitivity and infusion reactions

Bevacizumab (Avastin): hypersensitivity and infusion reactions Bevacizumab (Avastin): hypersensitivity and infusion reactions - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Bevacizumab (Avastin): hypersensitivity and infusion reactions Infusion reactions and hypersensitivity reactions have been reported commonly during treatment with Avastin. Published 11 December 2014 From: Therapeutic area: Article date: June 2010 Bevacizumab (Avastin) is a monoclonal antibody, which (...) inhibits vascular endothelial growth factor and is authorised for the treatment of various metastatic cancers. Healthcare professionals are advised to be aware that infusion reactions and hypersensitivity reactions have been reported commonly (≥1/100–<1/10) during treatment with Avastin. The incidence of such reactions is estimated to be up to 5% in clinical trials. Symptoms reported have included dyspnoea, flushing, rash, hypotension or hypertension, oxygen desaturation, chest pain, rigors, and nausea

2010 MHRA Drug Safety Update

17. Sublingual adrenaline tablets: How feasible is this novel approach to treatment of acute allergic reactions?

Sublingual adrenaline tablets: How feasible is this novel approach to treatment of acute allergic reactions? BestBets: Sublingual adrenaline tablets: How feasible is this novel approach to treatment of acute allergic reactions? Sublingual adrenaline tablets: How feasible is this novel approach to treatment of acute allergic reactions? Report By: Deepak Doshi - Specialist Registrar in Emergency Medicine Search checked by Bernard A Foëx - Consultant in Emergency Medicine and Critical Care (...) Institution: Manchester Royal Infirmary Date Submitted: 23rd May 2008 Date Completed: 14th October 2009 Last Modified: 1st September 2009 Status: Green (complete) Three Part Question In a [patient with an acute allergic reaction] does [a sublingual adrenaline tablet as compared to an intramuscular injection] work [better at reversing symptoms and preventing adverse effects of adrenaline?] Clinical Scenario A 34 year Jamaican man attended the Emergency Department after having his back tattooed. He had

2009 BestBETS

18. Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study. Full Text available with Trip Pro

Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study. To describe the outcomes of clinical evaluation, skin testing, and vaccine challenge in adolescent schoolgirls with suspected hypersensitivity to the quadrivalent human papillomavirus vaccine introduced in Australian schools in 2007.Retrospective cohort study.Two tertiary paediatric allergy centres in Victoria and South Australia, Australia.35 schoolgirls aged 12 to 18.9 years (...) with suspected hypersensitivity reactions to the quadrivalent human papillomavirus vaccine.Clinical review and skin prick and intradermal testing with the quadrivalent vaccine and subsequent challenge with the vaccine.35 schoolgirls with suspected hypersensitivity to the quadrivalent human papillomavirus vaccine were notified to the specialised immunisation services in 2007, after more than 380 000 doses had been administered in schools. Of these 35 schoolgirls, 25 agreed to further evaluation. Twenty three

2008 BMJ

19. Combination therapy with H2 and H1 antihistamines in acute, non compromising allergic reactions

antihistamines in histamine-induced wheal models of cutaneous allergy, and some of these suggest a benefit. Two studies have directly compared H1 against H2 (Moscati et al and Watson et al). Neither showed a benefit of H2 over H1 antihistamines. Two studies have compared H1 antihistamine against combined H1 and H2 antihistamines in the treatment of ongoing acute allergic reactions. Runge et al found no benefit. Only Lin et al have shown any benefit: relief of urticaria and improvement of angioedema (...) Combination therapy with H2 and H1 antihistamines in acute, non compromising allergic reactions BestBets: Combination therapy with H2 and H1 antihistamines in acute, non compromising allergic reactions Combination therapy with H2 and H1 antihistamines in acute, non compromising allergic reactions Report By: Dr TB Fogg and Dr D Semple - Clinical Fellow and SHO in Emergency Medicine Search checked by Dr H Simpson - Consultant in Emergency Medicine Institution: Emergency Department North Hampshire

2008 BestBETS

20. Specific Treatment Options - anaphylaxis/allergic reactions in adults

Specific Treatment Options - anaphylaxis/allergic reactions in adults INTRODUCTION Allergic reactions exist on a continuum from mild urticaria (hives) and/or angio-oedema (swelling of the face, eyelids, lips and tongue) to major pulmonary and/or cardiovascular compromise. The extreme end of the spectrum is anaphylaxis which can affect the cardiovascular, pulmonary, cutaneous, and gastrointestinal systems. It is an acute, life-threatening response in patients previously sensitised to an allergen (...) ): Available from http://www.resus.org.uk/pages/reaction.htm, 2005. Anaphylaxis/ Allergic Reactions in Adults Page 2 of 3 October 2006 Speci?c Treatment Options Speci?c Treatment Options5 Langran M, Laird C. Management of allergy, rashes and itching. Emergency Medical Journal 2004;21:728-741. 6 Lieberman P, Kemp S, Oppenheimer J, Lang D, Bernstein I, Nicklas R. The diagnosis and management of anaphylaxis: an updated practice parameter. Journal of Allergy and Clinical Immunology 2005;115:S483-523. 7

2007 Joint Royal Colleges Ambulance Liaison Committee